BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

By Yahoo! Finance | Oct 18, 2024 at 02:34 PM EST

BofA Securities upgraded Tyra Biosciences, a biotech company focusing on precision medicines. Tyra-300 showed promising preclinical results in hypochondroplasia. BofA raised the stock rating to Buy with a $31 price target ahead of TYRA-300's presentation.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.